{"links":{"feed":"https://www.erudio.com/reports/req-0000020479-nct03993249/feed.json","html":"https://www.erudio.com/reports/req-0000020479-nct03993249","json":"https://www.erudio.com/reports/req-0000020479-nct03993249.json","markdown":"https://www.erudio.com/reports/req-0000020479-nct03993249.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"req-0000020479-nct03993249"}},"request":"https://www.erudio.com/contact?report=req-0000020479-nct03993249"},"offer":{"cited_clinicians":7,"cited_commentary_sources":13,"verified_hcp_statements":34,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":13},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"req-0000020479-nct03993249"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=req-0000020479-nct03993249","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/req-0000020479-nct03993249","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 34 verified statements · 13 from 7 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-22T06:16:33.197180Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":1},"aspects":[{"claim_count":2,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: Locoregional control rate"},{"claim_count":5,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":5,"title":"Secondary endpoint: Incidence Rate of treatment-related adverse event (safety and tolerability)"},{"claim_count":3,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":3,"title":"Secondary endpoint: Bladder cancer failure-free (BCFF) rates"},{"claim_count":10,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes[2]","source_count":10,"title":"Secondary endpoint: Median overall survival (OS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule.secondaryOutcomes[3]","source_count":0,"title":"Secondary endpoint: Assessment of the effect of the combined treatment on the quality of life"},{"claim_count":5,"coverage":"discussed","id":"T6","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":8,"coverage":"discussed","id":"T7","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":6,"coverage":"discussed","id":"T8","registry_field":"outcomesModule","source_count":5,"title":"Safety and tolerability"},{"claim_count":11,"coverage":"discussed","id":"T9","registry_field":"designModule","source_count":5,"title":"Design and conduct"},{"claim_count":14,"coverage":"discussed","id":"A1","source_count":10,"title":"Phase III validation and clinical adoption"},{"claim_count":6,"coverage":"discussed","id":"A2","source_count":3,"title":"Chemotherapy compliance and interpretation of forthcoming studies"},{"claim_count":8,"coverage":"discussed","id":"A3","source_count":7,"title":"Endpoint terminology and proposed distant-relapse explanation"}],"counts":{"cited_clinicians":7,"cited_clinicians_by_role":{"physician, Medical oncology":1,"physician, Radiation oncology":6},"cited_physicians":7,"cited_sources":14,"claims_by_expression_type":{"comparison":1,"interpretation":11,"opinion":9,"primary_context":1,"question":2,"restatement":6,"uncertainty":4},"claims_by_kind":{"protocol_statement":1,"source_observation":33},"clinician_statements":13,"evidence_units":28,"findings":6,"organisational_accounts":3,"people_cited":14,"people_identity_verified":13,"people_total":14,"screened_sources":17,"verified_claims":34},"findings_index":[{"cited_clinicians":2,"id":"F1","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":9},"limitations":2,"links":{"context":0,"support":10},"ma_question":true,"named_voices":6,"passages":8,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Phase II efficacy: what most speakers highlight; some seek phase III testing","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-5aa5b3b6b68db9c45911","claim-97e50fe4d7b58243dfde","claim-b66c9e7b4cc0ab25c023","claim-9febf2507984273449dd","claim-c9e0569d2b84b37b63aa"],"clause":"some seek phase III testing","holders":3},"cited_claim_ids":["claim-3bd36a84542705a6654a","claim-cc2e7e9712486e29a424","claim-5aa5b3b6b68db9c45911","claim-b66c9e7b4cc0ab25c023","claim-c224daf1b77b6f1916c8","claim-c39ab95939e17266f14d","claim-66a64414592c015d5f95","claim-c9e0569d2b84b37b63aa"],"clinicians":false,"holders":5,"speakers":6,"view":"reading"},"evidence_line":"10 statements from 6 speakers in 6 sources, 1 of them a podcast or video","holder_line":"5 of the 6 named speakers in this finding hold this view; 3 of the 6 hold its caveat, “some seek phase III testing”"},{"cited_clinicians":2,"id":"F2","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":4},"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":5,"passages":5,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"Survival: what speakers note; one awaits primary local-control data","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-39a22f8501659f79b7f8"],"clause":"one awaits primary local-control data","holders":1},"cited_claim_ids":["claim-22439fb41e2932e54f6f","claim-7197102d73668f6cedea","claim-42f3f9cb8457d5b5d730","claim-228c297a40bd7de0fad3","claim-0bd02fbfc27638904513"],"clinicians":false,"holders":5,"speakers":5,"view":"reading"},"evidence_line":"6 statements from 5 speakers in 5 sources, 1 of them a podcast or video","holder_line":"5 of the 5 named speakers in this finding hold this view; 1 of them holds its caveat, “one awaits primary local-control data”"},{"cited_clinicians":2,"id":"F3","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":1,"views":2},"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Control arm: what speakers say","evidence_line":"5 statements from 2 speakers in 3 sources"},{"cited_clinicians":1,"id":"F4","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":4},"limitations":2,"links":{"context":0,"support":6},"ma_question":true,"named_voices":4,"passages":6,"sources":5,"sources_by_kind":{"commentary":5}},"title":"Safety signals: what speakers highlight; a clinician notes more immune toxicity","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-084a74890b5c58fc50d0"],"clause":"a clinician notes more immune toxicity","holders":1},"cited_claim_ids":["claim-22439fb41e2932e54f6f","claim-4e416361ad9eb586d265","claim-7197102d73668f6cedea","claim-084a74890b5c58fc50d0","claim-f4b3cd2feeaa2039f064","claim-36483f18eab1d366f678"],"clinicians":false,"holders":4,"speakers":4,"view":"reading"},"evidence_line":"6 statements from 4 speakers in 5 sources","holder_line":"4 of the 4 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician notes more immune toxicity”"},{"cited_clinicians":2,"id":"F5","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":3},"limitations":3,"links":{"context":0,"support":4},"ma_question":true,"named_voices":3,"passages":4,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Chemotherapy compliance: most clinicians await S1806; one notes agents differ","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-da6fe65274e5da770ab3"],"clause":"one notes agents differ","holders":1},"cited_claim_ids":["claim-f4b3cd2feeaa2039f064","claim-aa5863f8fc381268d711","claim-da6fe65274e5da770ab3"],"clinicians":true,"holders":2,"speakers":3,"view":"reading"},"evidence_line":"4 statements from 3 speakers in 2 sources","holder_line":"2 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one notes agents differ”"},{"cited_clinicians":2,"id":"F6","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":1,"views":1},"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":3,"passages":5,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"MIBC label: what speakers say","evidence_line":"4 statements from 3 speakers in 3 sources, 1 of them a podcast or video"}],"open_question":{"basis":"From finding F1 (10 statements from 6 speakers in 6 sources)","cited_claim_ids":["claim-3bd36a84542705a6654a","claim-cc2e7e9712486e29a424","claim-5aa5b3b6b68db9c45911","claim-97e50fe4d7b58243dfde","claim-b66c9e7b4cc0ab25c023","claim-c224daf1b77b6f1916c8","claim-c39ab95939e17266f14d","claim-66a64414592c015d5f95","claim-9febf2507984273449dd","claim-c9e0569d2b84b37b63aa"],"finding_ids":["F1"],"question":"What do clinicians say a randomized phase III trial must establish about overall survival before they would add nivolumab to chemoradiotherapy for muscle-invasive bladder cancer in patients not undergoing cystectomy?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Speakers see survival promise but call for phase III confirmation before adoption"},{"id":"section-2","level":2,"title":"Speakers distinguish survival promise from the local-control evidence"},{"id":"section-3","level":2,"title":"X accounts question the control arm; one also challenges conventional fractionation"},{"id":"section-4","level":2,"title":"X accounts pair safety reassurance with immune-toxicity and added-harm qualifications"},{"id":"section-5","level":2,"title":"Two X accounts focus on chemotherapy compliance; one flags immunotherapy-agent differences"},{"id":"section-6","level":2,"title":"One X account questions the population label; another clarifies non-metastatic MIBC"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":2}],"id":"T1","label":"Primary endpoint: Locoregional control rate"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":5}],"id":"T2","label":"Secondary endpoint: Incidence Rate of treatment-related adverse event (safety and tolerability)"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F4","shared_claims":2}],"id":"T3","label":"Secondary endpoint: Bladder cancer failure-free (BCFF) rates"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":5},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":1}],"id":"T4","label":"Secondary endpoint: Median overall survival (OS)"},{"findings":[],"id":"T5","label":"Secondary endpoint: Assessment of the effect of the combined treatment on the quality of life"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F6","shared_claims":4}],"id":"T6","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F3","shared_claims":5},{"id":"F5","shared_claims":1}],"id":"T7","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":6},{"id":"F5","shared_claims":1}],"id":"T8","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":1}],"id":"T9","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-22T06:16:33.197180Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-22T06:30:01Z","record_hash":"da1eceda6cb18d0d09d399d7fd8a9a473760023cb19d149ffbe56f38e2f6f367","release_hash":"339e9e25be2557cde8b9698e238b4e447f4597b4d7684a0565c2281e708e3160","report_id":"erudio-nct03993249","run_id":"6b1bb9c8-3a02-4c0f-a00e-8e5396db4476","schema_version":"5.0","slug":"req-0000020479-nct03993249","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"The clinicians cited read REQ-0000020479 as supporting phase III testing because of reported survival gains, rather than justifying routine use. A radiation oncologist reports that the local-control benefit was not statistically significant; another questions cisplatin as the sole chemotherapy agent. The statements leave the severity and management burden of added immune adverse events unclear. The sources reviewed for this edition place the phase II results at ESTRO2025.","examples":[],"meta_description":"17 sources screened · 34 verified statements (13 from clinicians verified by NPI or staff page) from 14 sources · 6 findings. Updated Nov 22, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-22T06:30:01Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":17},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","8 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 121 sources about other trials or topics are not included.","No full protocol was listed in the reviewed registry material, and no results publication was available for the exact trial. The registry evidence describes planned methods, not observed outcomes.","Several relevant statements describe the study’s regimen, population or clinical question without naming NCT03993249. They inform interpretation of the decision but should not automatically be treated as independently identified reports of this trial’s results.","Interview publication dates and X post dates do not establish presentation dates or a change of opinion. Expectations about endpoint maturity and forthcoming studies are preserved at the time they were expressed.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The reviewed statements do not resolve detailed endpoint equivalence, exact treatment-delivery differences, immune-event burden or quality-of-life effects."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":11,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":13,"methods":1},"count":14,"evidence_window":{"end":"2026-11-09","start":"2024-09-16"},"retrieval_snapshot":"2026-11-22T05:25:13.300343Z","timeline":[{"count":5,"week":"2024-W38"},{"count":2,"week":"2024-W44"},{"count":5,"week":"2025-W19"},{"count":1,"week":"2026-W46"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT03993249:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03993249:context","quote_policy":"short_quote_link_out"},{"id":"openfda:f570b9c4-6846-4de2-abfa-4d0a4ae4e394:20260812","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1336745259355820035:becde18d-c005-4940-8de3-938a6d9b4a03","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835583135863460016:2021bb0e-60d6-4931-affc-66630bb8c671","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835583361282126201:7909f462-56db-43a3-8d62-63726586f12e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835583450356851111:3a1fd63d-4159-4a54-96ae-41db092e8ea2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835585695550681338:03335aac-27d7-498f-9c91-b07dc841688d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835586518297039239:5262fbdb-1a4e-41c5-9782-cb68debe322c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835592349256237418:f8d8ca8f-2f76-46c8-b089-ef88a3aee4a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835661297536405571:ec8b2429-0f7e-432b-b6ba-c188a85663d7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835800954811097358:f5cad74a-b2b2-42d4-aad7-b40aeb4901ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1919313613753311249:aec3a26b-2174-40a7-ac80-4431d250edf9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1919314744621613512:23165462-0daf-4ae5-8413-2aa11dd58d52","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1919315158817468833:7ce04968-064c-40c2-aa61-b4f26da6f959","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1919325236756922576:982b84fc-e0b8-43e4-80d8-31431d5d41db","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1919337694846443942:b9f5bf0c-9470-4410-8be5-0e62acf8a891","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2119901490315657656:33103faf-9c04-46f6-8898-fe015d1816dc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:D0-xzbSM_VQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Q-a_D-E24lc","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":15,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":17},"count":17,"evidence_window":{"end":"2026-11-09","start":"2020-12-09"},"retrieval_snapshot":"2026-11-22T05:25:13.300343Z","timeline":[{"count":1,"week":"2020-W50"},{"count":8,"week":"2024-W38"},{"count":2,"week":"2024-W44"},{"count":5,"week":"2025-W19"},{"count":1,"week":"2026-W46"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":26,"x_video":0,"youtube":7}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Opdivo"],"label":"nivolumab","slug":"nivolumab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Urothelial carcinoma","slug":"urothelial-carcinoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"aliases":["Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy","Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy: a Phase II, Randomized Study"],"brief_title":"Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Bladder Cancer"],"display_condition":"muscle-invasive bladder cancer","display_interventions":[["nivolumab"]],"enrollment":{"count":78,"type":"ESTIMATED"},"interventions":[{"name":"Nivolumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"BIOLOGICAL"},{"name":"chemoradiotherapy","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"OTHER"}],"nct_id":"NCT03993249","official_title":"Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy: a Phase II, Randomized Study","overall_status":"UNKNOWN","phase":["PHASE2"],"primary_completion_date":{"date":"2022-08","type":"ESTIMATED"},"primary_endpoints":[{"description":"To compare locoregional control rate at 2-years between patients with MIBC receiving or not receiving nivolumab in addition to chemoradiotherapy","measure":"Locoregional control rate","timeFrame":"2 years"}],"registered_date":{"date":"2019-06-20","type":"ACTUAL"},"registry_last_updated":"2022-03-23","registry_url":"https://clinicaltrials.gov/study/NCT03993249","short_name":"REQ-0000020479","short_name_basis":"sponsor_study_id","sponsor":"Hellenic GenitoUrinary Cancer Group","start_date":{"date":"2019-05-28","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2","study_ids":[{"id":"REQ-0000020479","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}